2-甲基-5-硝基三氟甲苯 | 89976-12-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟甲苯系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-5-硝基三氟甲苯
• 中文别名: 3-三氟甲基-4-甲基硝基苯；4-硝基-2-三氟甲基甲苯；5-硝基-2-甲基三氟甲苯
• 英文名称: 1-methyl-4-nitro-2-(trifluoromethyl)benzene
• 英文别名: 2-methyl-5-nitrobenzotrifluoride；3-trifluoromethyl-4-methylnitrobenzene
• CAS: 89976-12-5
• 化学式: C₈H₆F₃NO₂
• mdl: MFCD01631684
• 分子量: 205.136
• InChiKey: SVQCVQCIZWSPPX-UHFFFAOYSA-N

物化性质

• 熔点：
  34-35 °C
• 沸点：
  220.5±35.0 °C(Predicted)
• 密度：
  1.357±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT-HARMFUL
• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S23,S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2904909090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methyl-5-nitrobenzotrifluoride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyl-5-nitrobenzotrifluoride
CAS number: 89976-12-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6F3NO2
Molecular weight: 205.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (2-Methyl-5-nitrobenzotrifluoride)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-甲基-5-硝基三氟甲苯作为一种有机合成的中间体，在农药产品的合成中扮演重要角色。此外，它也被广泛应用在医药和精细化工领域。

合成方法

2-甲基-5-硝基三氟甲苯的合成过程如下：将43.0克（0．20摩尔）2-甲基三氟甲苯加入反应瓶中，并在冰浴条件下冷却至－5℃。随后，缓慢滴入由27.9克（0．42摩尔）95%硝酸与168.1克（1．68摩尔）98%浓硫酸配置的稀酸混合物，确保温度维持在低于0℃。滴毕后，继续控制反应温度在－5～0℃之间搅拌反应2小时。

接着加入130.1克（1．0摩尔）丙酸酐，并缓慢加热至80℃保温反应6小时。完成后，将反应混合物冷却至50℃，再加入61克（0．57摩尔）邻二甲苯，搅拌30分钟后静置分离有机相。用水洗涤、降温后析晶得2-甲基-5-硝基三氟甲苯纯品54.9克，收率高达90%。

在该过程中，下层废酸通过减压蒸馏可回收多余的丙酸酐，并直接用于代替浓硫酸的再利用；同时，收集并集中处理丙酸和丙酸酐后进行精馏回收，以实现丙酸酐的循环使用。

反应信息

• 作为反应物：
  描述：

  2-甲基-5-硝基三氟甲苯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， -20.0~80.0 ℃ 、101.33 kPa 条件下， 反应 26.5h， 生成 1-(5-bromo-1-methyl-1H-pyrazol-3-yl)-3-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)urea
  参考文献：
  名称：

  [EN] IRE1 SMALL MOLECULE INHIBITORS
  [FR] INHIBITEURS DE PETITES MOLÉCULES IRE1

  摘要：

  本文提供了针对IRE1蛋白家族成员的小分子抑制剂。结合可以是直接的或间接的。此外，本文提供了使用IRE1小分子抑制剂用于治疗或改善受试者癌症的方法。此外，本文描述的IRE1小分子抑制剂用于治疗癌症，其中癌症是实体或血液系统的癌症。

  公开号：

  WO2018102751A1
• 作为产物：
  描述：

  4-甲基-4-(三氯甲基)环己-2,5-二烯-1-酮 在 ammonium hydroxide 、 五氯化磷 、 硫酸 、 硝酸 、 三氟化锑 、 三氯氧磷 作用下， 生成 2-甲基-5-硝基三氟甲苯
  参考文献：
  名称：

  Yagupol'skii,L.M.; Matyushecheva,G.I., Journal of general chemistry of the USSR, 1963, vol. 33, p. 2957 - 2960

  摘要：

  DOI：
• 作为试剂：
  描述：

  N-乙基哌嗪 、 1-(溴甲基)-4-硝基-2-(三氟甲基)苯 在 2-甲基-5-硝基三氟甲苯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 1-乙基-4-(4-硝基-2-(三氟甲基)苄基)哌嗪
  参考文献：
  名称：

  Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

  摘要：

  In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pan-inhibitors of BCR-ABL, including the T315I mutation. A key structural feature is the carbon-carbon triple bond linker which skirts the increased bulk of I1e315 side chain. Extensive SAR studies led to the discovery of development candidate 20g (AP24534), which inhibited the kinase activity of both native BCR-ABL and the T315I mutant with low nM IC(50)s, and potently inhibited proliferation of corresponding Ba/F3-derived cell lines. Daily oral administration of 20g significantly prolonged survival of mice injected intravenously with BCR-ABL(T315I) expressing Ba/F3 cells. These data, coupled with a favorable ADME profile, support the potential of 20g to be an effective treatment for CM L, including patients refractory to all currently approved therapies.

  DOI：

  10.1021/jm100395q

文献信息

• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance
  作者：Lu Wang、Qing Zhang、Gaoyuan Zhu、Zhimin Zhang、Yanle Zhi、Li Zhang、Tianxiao Mao、Xiang Zhou、Yadong Chen、Tao Lu、Weifang Tang

  DOI：10.1016/j.ejmech.2017.02.041

  日期：2017.4

  isoforms offers the prospect of enhanced efficacy as well as reduced potential for resistance. Described herein is the discovery and characterization of a series of pyrimidine scaffold with DFG-out conformation as potent Pan-Raf inhibitors. Among them, I-41 with excellent Pan-Raf potency demonstrates inhibitory activity against BRafWT phenotypic melanoma and BRafV600E phenotypic colon cells. The western

  同时靶向所有Raf同工型提供了增强的功效以及降低的抗药性的前景。本文描述了一系列具有强力泛肽抑制剂的具有DFG-out构象的嘧啶支架的发现和表征。其中，具有优异泛泛效能的I-41表现出对BRafWT表型黑素瘤和BRafV600E表型结肠细胞的抑制活性。Western blotting结果显示，人黑素瘤SK-Mel-2细胞系中Erk的抑制作用表明I-41抑制了SK-Mel-2细胞的增殖而没有Erk的反常激活，这支持I-41可能成为良好的候选化合物。克服黑素瘤对当前BRafV600E抑制剂疗法的耐药性。I-41在大鼠中也具有良好的药代动力学特征。合成，SAR，线索选择，
• Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT
  作者：Helena Kaitsiotou、Marina Keul、Julia Hardick、Thomas Mühlenberg、Julia Ketzer、Christiane Ehrt、Jasmin Krüll、Federico Medda、Oliver Koch、Fabrizio Giordanetto、Sebastian Bauer、Daniel Rauh

  DOI：10.1021/acs.jmedchem.7b00841

  日期：2017.11.9

  In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted

  在现代癌症治疗中，已证明使用抗受体酪氨酸激酶（RTK）的有机小分子是一种有价值的策略。癌细胞与与RTK连锁的失调的信号通路的关联代表了靶向癌症治疗中的关键要素。酪氨酸激酶肥大/干细胞生长因子受体KIT是临床相关RTK的一个例子。KIT的目标是在胃肠道间质瘤（GIST）和慢性粒细胞性白血病（CML）中进行癌症治疗。但是，在催化域内获得性耐药突变降低了该策略的效力，并且是治疗失败的最常见原因。在这里，我们介绍了新型II型激酶抑制剂的结构化设计和合成，以克服KIT中的这些突变。
• [EN] METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR LA KINASE RAF
  申请人：ARIAD PHARMA INC

  公开号：WO2013162727A1

  公开（公告）日：2013-10-31

  The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein.

  该发明揭示了通过给予化合物Formula 1或其药学上可接受的盐、溶剂或水合物来治疗或预防由RAF激酶介导的疾病或症状的方法和组合物，其中变量如本文所定义。
• <i>B</i>-Alkyl Suzuki−Miyaura Cross-Coupling Reactions with Air-Stable Potassium Alkyltrifluoroborates
  作者：Gary A. Molander、Chang-Soo Yun、María Ribagorda、Betina Biolatto

  DOI：10.1021/jo0343331

  日期：2003.7.1

  palladium-catalyzed cross-coupling reaction of substituted potassium alkyltrifluoroborates with aryl halides and aryl triflates proceeds readily with moderate to good yields. The potassium alkyltrifluoroborates 1, 2, and 3a-e were easily synthesized and obtained as air-stable crystalline solids that can be stored for long periods of time. All of the cross-couplings proceed under the same reaction conditions using PdCl(2)(dppf)

  取代的烷基三氟硼酸钾与芳基卤化物和芳基三氟甲磺酸酯的钯催化交叉偶联反应易于进行，产率中等至良好。烷基三氟硼酸钾1、2和3a-e易于合成，并以空气稳定的结晶固体形式获得，可以长期保存。所有交叉偶联均在相同的反应条件下使用PdCl（2）（dppf）.CH（2）Cl（2）作为催化剂在THF-H（2）O中在3当量的Cs（2）存在下进行以CO（3）为基。